...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
AGORACOM NEWS FLASH

Dear Agoracom Family,

I want to thank all of you for your patience with us over the past 48 hours and apologize for what was admittedly a botched launch of our new site.

As you can see, we have reverted back to the previous version of the site while we address multiple forum functionality flaws that inexplicably made their way into the launch.

To this end:

1.We have identified 8 fundamental but easily fixable flaws that will be corrected in the coming week, so that you can continue to use the forums exactly as you've been accustomed to.

2.Additionally we will also be implementing a couple of design improvements to "tighten up" the look and feel of the forums.

Sincerely,

George et al

Message: RVX AGM Q&A, post AGM-huddle, impressions

 If I understand correctly:

12 million potential patients in the top 8 markets could be treated for one of the 3 diseases being tested in the BETonMACE trial.

From what I understand it seems that between $5000-$6000 per year per patient for treatment.

So if we just capture 10% of market or 1.2 million patients:

1,200,000 X $5000 = $6 billion

$6 billion / 200 millions shares (balpark shares outstanding) = 30 times,... 

,... and that is just for 10%,... and that is just for the top 8 markets,... and that is just for 3 indications,... and it seems there are at least 20 more!

Looking foward to when the US markets get to hear what the analysts say once Top-Line results are announced!!

  

 

 

 

 

 

Share
New Message
Please login to post a reply